Allison is Associate Editorial Director for The American Journal of Managed Care® (AJMC®) and The Center for Biosimilars®. She joined AJMC® in 2017. She produces and oversees written, video, and podcast content across several disease states and issues surrounding value-based care and health policy.
She has an MPA from New York University. You can connect with Allison on LinkedIn.
Review Suggests Having IBD May Increase Risk of PD
December 1st 2021The meta-analysis sought to clarify previous research, which has explored the idea that Parkinson disease (PD) is tied to inflammation in the gastrointestinal tract, noting that inflammatory bowel disease (IBD) has been implicated in neuroinflammation.
Dr Don Sin Describes Promising COPD Biomarkers
November 22nd 2021Blood eosinophil count is a promising biomarker and example of the pathway toward precision medicine in chronic obstructive pulmonary disease (COPD), said Don Sin, MD, FRCP, MPH, a professor of respiratory medicine at the University of British Columbia and head of the Centre of Heart Lung Innovation, St. Paul’s Hospital.
Guideline for Treating Motor Symptoms of PD Gets First Update Since 2002
November 17th 2021The guideline reflects findings regarding confidence in evidence about how to care for the motor symptoms in patients with early Parkinson disease (PD), including the comparative efficacy of treatments as well as the comparative risk of adverse events.
Survey of Australian Oncologists Finds Room for Increasing Their Confidence With CGP
November 12th 2021A recent survey of oncologists in Australia showed that while most are integrating comprehensive genomic profiling (CGP) into their practice, they lack a high level of confidence to communicate findings and to adjust patient treatment accordingly.
High Iron Levels in Blood Linked to Increased Risk of Liver Cancer in NAFLD
November 12th 2021Researchers conducted the study because although prior research has illustrated that elevated levels of iron in the blood from hereditary hemochromatosis can raise the risk of liver cancer, little is known about the effect of this condition in nonalcoholic fatty liver disease (NAFLD).
Anticholinergic Polypharmacy in Medicare Not Common but Still Problematic, Study Says
November 10th 2021The share of patients meeting the definition of polypharmacy for the condition of overactive bladder declined from 2006 to 2017, but the phenomenon was still prevalent in women and patients in nursing homes, according to a recent study.
For Optimal Cost-effectiveness, Strategize Biologic Therapy for Severe Asthma
November 8th 2021To avoid bankrupting health care, providers must carefully consider how they use biologics in patients with severe asthma, according to a presenter at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.
To Prevent the Next Pandemic, Fight Antiscience Beliefs, Hotez Says
November 7th 2021While low- and middle-income countries remain desperate for a COVID-19 vaccine, the United States has entered a dangerous new phase of the pandemic, where antivaccine forces are exporting their antiscience beliefs to other countries, according to a keynote speaker at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.
Daprodustat Shows Favorable Safety in Treating Anemia in CKD With, Without Dialysis
November 6th 2021Daprodustat had no increased cardiovascular risk, compared with erythropoiesis stimulating agents (ESAs), in treating anemia in patients with chronic kidney disease (CKD) who were on dialysis and not on dialysis.
Study Suggests Improved Screening Strategies for Fabry Disease
October 29th 2021Early diagnosis of Fabry disease is essential and that since symptoms depend on the type of disease and sex and age of the patient, a high-risk screening system should account for the age of the target population, the researchers said.
Additional Data on Possible Chronic Cough Therapy Presented at CHEST 2021
October 20th 2021There are currently no FDA-approved treatments for refractory chronic cough or unexplained chronic cough. At the CHEST Annual Meeting 2021, attendees heard a readout from a durability study as well as pooled analyses from 2 phase 3 trials for gefapixant.
Effects of Type 2 Inflammation in Allergic Disease: Visible, Invisible, Complex
October 20th 2021There has been a huge shift forward in the understanding of innate and adaptive immune mechanisms that provoke type 2 inflammation in atopic disease and eosinophilic esophagitis, according to a CHEST Annual Meeting 2021 speaker.
Tremelimumab Added to Durvalumab Shows Positive Results in HCC
October 15th 2021There was statistically significant and clinically meaningful overall survival benefit vs sorafenib as a first-line treatment for patients with unresectable hepatocellular carcinoma (HCC) in top-line results from a phase 3 trial.